The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Users of popular GLP-1 weight loss drugs are reporting a peculiar side effect: an intense new passion for perfumes, particularly sweet and gourmand scents. This phenomenon, nicknamed 'Ozempic smell,' is transforming wardrobes and wallets.
As 'Mounjaro brides' become a trend, an endocrinologist unpacks the medical realities, risks, and ethical concerns surrounding using powerful weight-loss medications for cosmetic pre-wedding transformations.
The soaring popularity and effectiveness of GLP-1 medications for weight loss are undeniably reshaping healthcare landscapes. But as demand surges, so do the costs, leading to significant implications for both employers and the individuals who rely on these treatments. This article delves into the financial pressures, employer strategies, and what you can expect regarding your co-pays and coverage for drugs like Ozempic, Wegovy, and Mounjaro.
Initially celebrated for their weight-loss efficacy, GLP-1 receptor agonists are now revealing a broader therapeutic scope. Emerging research suggests these powerful medications may offer significant benefits in combating inflammation and tissue damage, potentially transforming the management of chronic diseases.
Novo Nordisk's groundbreaking Wegovy pill has received a significant recommendation for approval from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This marks a pivotal step towards potentially broadening access to advanced weight management solutions for adults across the European Union.
Discover the natural power of MCT oil, a coconut derivative that's gaining attention for its potential to aid weight loss, boost energy, and enhance mental clarity. Learn how it works and if it's the right choice for you.
The soaring popularity and effectiveness of GLP-1 medications for weight loss are driving up healthcare costs, leading to potential increases in employee co-pays and changes in employer coverage strategies. This article explores the financial implications and what you need to know.
While GLP-1 agonists are revolutionizing weight management, emerging research suggests a potential downside: nutrient deficiencies. This article delves into what the latest studies reveal about these vital nutrient gaps and how to address them.
New research leverages AI to sift through vast online discussions, identifying patient-reported side effects of popular GLP-1 medications that may not be fully captured in clinical trials.
